A concise review on analytical profile of Vigabatrin
1 Department of Pharmaceutical Chemistry, Smt. Sharadchandrika Suresh Patil College of Pharmacy, Chopda, Maharashtra, India.
2 Department of Pharmacology, VYWS, Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha 442001, India.
3 Department of Pharmaceutics, Smt. Sharadchandrika Suresh Patil College of Pharmacy, Chopda, Maharashtra, India.
Review Article
World Journal of Advanced Research and Reviews, 2023, 17(02), 061–067
Article DOI: 10.30574/wjarr.2023.17.2.0178
Publication history:
Received on 19 December 2022; revised on 29 January 2023; accepted on 01 February 2023
Abstract:
Vigabatrin (VGB) is a drug of Anticonvulsant class. It works by decreasing abnormal electrical activity in the brain. It inhibits the GABA-degrading enzyme i.e. GABA transaminase, it increases the GABA concentrations in the brain. Vigabatrin is used for the treatment of refractory complex partial seizures in adults and also used for children 2 years of age and older and infantile spasms in children. Vigabatrin was approved for anticonvulsant medication by USFDA on August 21, 2009. Therefore, in the present review article, we have enlisted different analytical method such as Ultraviolet (UV) visible spectroscopy, High-performance liquid chromatography (HPLC), Ultra-performance liquid chromatography (UPLC) and Gas Chromatography for both qualitative and quantitative analysis of VGB in pharmaceutical and biological. In the future, this review article will assist researchers regarding the development of a new analytical method for VGB.
Keywords:
Vigabatrin; Anticonvulsant; USFDA; Analytical Method; HPLC; Bioanalytical Method
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0